Craddock et al. (2010) evaluated a GD2-directed CAR-T that was additionally modified to express CCR2. They found increased tumor homing and antitumor activity in a preclinical neuroblastoma model. Mesothelin-specific CAR-T cells expressing CCR2b have also been shown to traffic effectively and eradicate established mesothelioma tumor xenografts and preclinical models of lung cancer (Moon et al., 2011; Wang et al., 2021). This evidence concerns the gene MSLN and lung cancer.